A clean, high-resolution digital photograph features a white plastic supplement bottle labeled “Bioglutide 100 mg, Batch No.002, 24-09-2025” in black text. The bottle is positioned upright on a neutral beige background with two cream-colored capsules placed beside it.

Bioglutide 100x100mg

€200,00 EUR
跳至产品信息
A clean, high-resolution digital photograph features a white plastic supplement bottle labeled “Bioglutide 100 mg, Batch No.002, 24-09-2025” in black text. The bottle is positioned upright on a neutral beige background with two cream-colored capsules placed beside it.
Bioglutide 100x100mg

Bioglutide 100x100mg

€200,00 EUR
已含税费。

                                           NOT FOR HUMAN CONSUMPTION

Bioglutide (NA-931)  is positioned as a once-daily pill aiming to combine incretin satiety/glycaemic control (GLP-1, GIP), energy-expenditure and hepatic lipid effects (glucagon), and anabolism/lean-mass support (claimed IGF-1 receptor activity). If verified, the mix would theoretically pair deep appetite suppression with higher energy expenditure and better body-composition quality than GLP-1 monotherapy. Evidence confirming direct IGF-1 receptor agonism by a small molecule is sparse in the literature, so this aspect should be viewed as unproven pending peer-review. 

Additional Benefits of Bioglutide Now Under Investigation

Benefit Key take-aways
1 Oral, multi-pathway weight loss Company-reported Phase 2 data (13 weeks) cite double-digit mean weight loss at higher doses, with placebo-adjusted reductions >10% in top arms. Independent, peer-reviewed confirmation is pending. 
2 Glycaemic control in T2D Aims to deliver A1c reductions comparable to injectable incretins while being oral; formal peer-reviewed T2D results have not yet been published. 
3 Energy-expenditure boost (GCGR) Glucagon receptor engagement is expected to raise resting energy expenditure and promote fat oxidation, potentially countering metabolic adaptation seen with weight loss. Human EE data for NA-931 have not been publicly vetted. 
4 Lean-mass preservation (IGF-axis) By adding an IGF-1 component, NA-931 is pitched to preserve muscle during weight loss; direct evidence in humans has not been disclosed in peer-review. 
5 Liver fat & MASH signals A quadruple profile could reduce MRI-PDFF and improve ALT/AST (weight loss + glucagon hepatolipid effects); trials in metabolic liver disease are referenced as ongoing/planned. 
6 Convenience & adherence Oral dosing may improve uptake and persistence vs injectables for some patients, assuming tolerability is favorable. 
7 Combination potential Company materials suggest add-on use with GLP-1/GIP injectables (e.g., semaglutide/tirzepatide) for extra weight loss; this is hypothesis-generating only. 
8 Cardiometabolic risk factors Expectation (by mechanism/class): BP and triglyceride reductions, non-HDL/apoB improvements; formal datasets for NA-931 are not yet public. 
9 Patient-reported outcomes Anticipated gains in satiety, cravings, physical function—data not yet peer-reviewed for NA-931. 

2. Molecular Mechanism of Action

2.1 Receptor pharmacodynamics (claimed)

  • GLP-1R: ↓ appetite, ↓ gastric emptying; glucose-dependent insulin↑, glucagon↓ post-meal.

  • GIPR: Potentiates insulin secretion; may improve adipocyte metabolic flexibility and GI tolerability with GLP-1.

  • GCGR (glucagon): ↑ energy expenditure and fat oxidation; mobilizes hepatic lipid with careful glycaemic counter-balance.

  • IGF-1R (claimed): Anabolic/anti-catabolic signaling (Akt–mTOR); preservation of lean mass. Note: Direct, selective small-molecule IGF-1R agonism is biologically unusual and currently unverified for NA-931 outside company statements. 

2.2 Down-stream biology

Pathway Functional outcome Context
POMC/AgRP (CNS) Satiety ↑, cravings ↓ Appetite circuits
Islet incretin signaling Glucose-dependent insulin ↑ Pancreas
Hepatic lipid handling (GCGR) Fat oxidation ↑, steatosis ↓ Liver
Akt–mTOR (IGF-axis) Protein synthesis/lean mass support Muscle (theoretical for NA-931)

3. Pharmacokinetics

  • Formulation/Route: Oral tablet, once daily (company reports).

  • Half-life/Exposure: Not published in peer-review; dose-ranging has been presented in company communications.

  • Food effect/Absorption: Not disclosed in detail.

  • Drug–drug: No public interaction matrix yet. 

4. Pre-clinical & Clinical Evidence (what’s public)

  • Phase 2 obesity (company-reported): ~13-week study with dose-dependent weight loss; a high-dose arm reportedly ~14–15% total body-weight reduction and ~13% placebo-adjusted—awaiting peer-review and full protocol transparency. 

  • Development status: Communicated as moving toward Phase 2b/3 in obesity/T2D; registry and pipeline round-ups list NA-931 in mid-stage development. 

Evidence quality note: To date, nearly all information comes from company press releases, industry trade coverage, or pipeline summaries—not peer-reviewed journals. Treat efficacy magnitudes and receptor claims as preliminary.

5. Emerging Clinical Interests

Field Rationale Status
Chronic weight management Oral option with multi-hormone pharmacology Phase 2→2b/3 (company)
Type 2 diabetes A1c + weight + potential metabolic flexibility Planned/ongoing per company
MASH/NAFLD Weight + glucagon-driven hepatic lipid effects Exploratory
Combination with injectables Additive weight loss hypothesis Preclinical/company claims

6. Safety and Tolerability (what to expect, what we don’t know)

  • Likely class AEs (if incretin-dominant): Nausea, vomiting, diarrhea/constipation, abdominal pain (generally titration-dependent).

  • Glucagon component: Possible ↑ heart rate, glycaemic counter-pressure (balanced by GLP-1/GIP); monitor BP/HR.

  • IGF-axis concerns (theoretical): If genuine IGF-1R agonism occurs, watch edema, hypoglycaemia (low risk), and mitogenic signaling—though this is unconfirmed for NA-931.

  • Unknowns: Long-term safety, gallbladder events with large weight loss, pancreato-biliary risks, drug–drug interactions.

  • Contraindications/caution (by class analogy): History of MEN2/MTC (GLP-1 class warning), gastroparesis, pregnancy. Final labeling, if any, will determine specifics. 

Comparative snapshot (tentative)

Feature Bioglutide (NA-931) Tirzepatide Semaglutide
Modality Oral small molecule Injectable peptide Oral & injectable peptide
Targets GLP-1/GIP/GCGR + IGF-1 (claimed) GLP-1 + GIP GLP-1
Weight-loss magnitude Company-reported double-digit at 13 wks 15–22% at 72 wks (RCTs) 12–17% at 68–104 wks (RCTs)
Peer-reviewed evidence Not yet Robust Robust

7. Regulatory Landscape

  • Not approved by FDA/EMA; investigational.

  • Public materials describe Phase 2→2b/3 programs in obesity and T2D, with additional studies proposed (e.g., MASH).

8. Practical Take 

  • Promising concept, but extraordinary claims (quadruple agonism incl. IGF-1R) demand extraordinary evidence.

  • Until peer-reviewed trial reports with detailed methods, safety tables, pharmacokinetics, and receptor pharmacology are available, treat Bioglutide’s efficacy and mechanism as provisional.

  • For patients today, approved incretin therapies (semaglutide, tirzepatide, etc.) remain the evidence-basedchoices; Bioglutide is a watch-this-space candidate.

Selected References

  • Company materials: Biomed Industries—NA-931 (Bioglutide) product page, press releases, and Phase-2 summaries (quadruple agonist, oral, obesity/T2D). 

  • Industry coverage: FirstWord Pharma news on NA-931 program updates and claimed trial readouts.

  • Pipeline round-ups: Prime Therapeutics GLP-1 pipeline brief; Larvol Delta product tracker; Patsnap/Synapse drug entry summarizing company-reported Phase 2 figures.

  • Context reviews: Triple-agonist reviews outlining rationale for GLP-1/GIP/GCGR combinations (without IGF-1R).